by Chris Wack
Shares of Geovax Labs Inc. rose 17% to $2.68 after the company said China’s Patent Office issued a notice of allowance for its patent application titled “Compositions and Methods to Generate an Immune Response to Tumor Associated Antigens”. has done.
Volume for the stock was 32 million shares at 12:20 p.m. ET, compared to its 65-day average volume of 6.5 million shares.
The company said the claims made by the patent generally cover its vector platform for expressing tumor-associated antigens in virus-like particles from a modified Vaccinia Ankara viral vector and Geovax’s mucin 1 tumor-associated antigen immunotherapy. include the candidate.
The company uses its GV-MVA-VLP vaccine platform to target potential treatments for a wide range of cancers, including breast, colon, ovarian, prostate, pancreatic and lung.
The stock closed Monday’s session up 67%, but was down 1% on Tuesday, in line with many other vaccine-related stocks, amid concerns about monkeypox. Also on Monday, Maxim Group set a $6 price target for Geovax stock.
The stock hit its 52-week low of 55 cents on May 22.
Write to Chris Wack at [email protected]
Credit: www.marketwatch.com /